Novo Nordisk core business undervalued versus Lilly
The guest argued that Novo Nordisk's core diabetes and obesity business is being undervalued by the street, especially in comparison to Eli Lilly, despite strong execution and a successful Wegovy pill launch.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.